Early diagnosis of sarcoidosis starts with a careful medical history, physical examination and appropriate imaging. Depending on symptoms, clinicians may request blood tests, lung function tests, eye or heart assessments and, when necessary, a biopsy. Because other conditions can look similar, the diagnosis should be confirmed by an experienced medical team. This information is educational and does not replace a medical consultation.


Earlier specialist assessments are needed

Historical article based on the original report by Marisa Horak (Sarcoidosis News), published on 10 March 2023. The statement about participant recruitment refers to the situation at the time of the original publication.

Patients welcome earlier specialist referrals and better therapies. Their discussion put quality of life at the centre of their experiences. According to a discussion involving patients from six countries, people with pulmonary sarcoidosis believed earlier referrals could improve diagnosis and called for new treatments that could improve their quality of life. They also questioned the idea of remission in a disease that can affect several organs, and were willing to accept reasonable side effects from treatments that limited disease progression.

The study “Living with sarcoidosis: Virtual roundtable dialogue with patients and healthcare professionals” was published in Respiratory Medicine.

The path to a sarcoidosis diagnosis is “often convoluted”

Sarcoidosis is caused by inflammatory clusters of immune cells that can affect organs throughout the body, causing a wide range of symptoms in patients. “[The unpredictability of the disease] complicates the study of patients’ experiences,” the researchers wrote.

A team of scientists from the United States, Italy and Novartis used a virtual platform to organise a discussion with a group of nine patients with sarcoidosis from the United States, Australia, Japan, Denmark, Germany and Italy. Three expert clinicians were also available to provide explanations and comments.

Novartis, which also funded the study, is testing its therapy candidate CMK389 in people with pulmonary sarcoidosis in a Phase 2 trial (NCT04064242). The study is enrolling eligible patients at sites across the United States and Europe.

The roundtable included a combination of closed and open-ended questions, with the aim of better understanding “patients’ lived experiences, unmet needs, and views on existing and hypothetical upcoming treatment options,” the researchers wrote.

 

The patients ranged in age from 44 to 73 years, and four were women. They had lived with sarcoidosis for at least three years to more than three decades, and all had pulmonary sarcoidosis.

Five rated their own disease as mild, two as moderate and two as severe. For most patients, their assessment of disease severity varied from day to day, the researchers noted. Their journey with sarcoidosis generally began with symptoms such as a persistent cough or shortness of breath that prompted them to seek medical help. A complex process followed before the correct diagnosis was reached.

 

“Often, the first [healthcare providers] contacted were unaware of sarcoidosis and focused on other possibilities such as cancer or tuberculosis. The path to diagnosis was often convoluted, with up to 4 doctors involved along the way,” the researchers wrote.

 

Therapy that promotes a good quality of life is valued most

Despite these difficulties, the discussion group generally expressed satisfaction with their clinicians during the diagnostic process. Nevertheless, the group agreed that the diagnostic process could be improved by referring patients to specialists more quickly.

The patients attributed the severity of their disease to “reduced physical activity, treatment side effects, the need to adhere to a treatment schedule, and the psychological burden of asking others for help,” the team wrote.

Most patients described themselves as “living with the disease” rather than “being ill”, a distinction that many considered important.

“Living with this condition involved reducing and adapting leisure activities, finding new ways for families and couples to spend time together, and developing a mindset that gave them the ‘opportunity to appreciate every moment in life’,” the researchers wrote.

 

Most patients were initially treated with corticosteroids such as prednisone and corticosteroid-sparing medicines such as methotrexate. They generally continued using these medicines over the long term: although many tried to reduce their corticosteroid dose, in most cases this led to a disease flare.

When asked about the most important factors in trying a hypothetical new treatment, patients generally valued a therapy’s ability to improve their lives most highly, followed by reducing disease progression and severity.

“I can live with some side effects if the treatment improves my symptoms, quality of life and activity level,” one patient said.

A therapy’s side-effect profile was considered less important than its effect on quality of life, although patients noted that the two were connected. “If the side effects knock me flat, the treatment does not improve my quality of life,” a patient said.

 

All expressed fear of future disease flares, particularly because these would mean needing to increase corticosteroid doses, which can cause side effects such as mood changes, weight gain and high blood pressure.

 

“Fear of disease progression and spread to other organs was also common,” the researchers wrote, noting that many participants were sceptical of the idea that their disease was in remission because there was always a risk of future worsening.

The participants noted the need for better tools to help predict the likely course of sarcoidosis. They also highlighted the need for new therapies that could target the underlying cause of sarcoidosis and work to prevent the disease from worsening, rather than merely managing symptoms.

 

“In summary, this interactive exchange provided important insights into how people with sarcoidosis experience their condition through dialogue with other patients and with expert clinicians available for clarification,” the researchers wrote.

“Important concerns expressed by patients with sarcoidosis included the need for faster referrals to specialists, distrust of the concept of remission in sarcoidosis, and the need for new therapies aimed at reducing disease progression and improving symptoms and [quality of life], rather than withdrawing corticosteroids,” they added.

 

Source: https://sarcoidosisnews.com/news/patients-want-earlier-specialist-referrals-better-treatments/

Rating: 0 stars, 0 votes.